India needs to remain attractive for innovation-led investment: Judith Love, Novartis

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The company underscores the importance of collaboration to tackle obstacles like high costs and inadequate infrastructure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GP6dNjY
via IFTTT

Read More

US drug regulator issues import alert for drugs made at a Dabur India plant

The US Food and Drug Administration has placed Dabur India's factory on an import alert. This action follows an inspection that revealed significant issues with data integrity and factory maintenance. Critical manufacturing records were reportedly falsified. Live birds and droppings were also found in a raw material warehouse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pa87rF2
via IFTTT

Read More

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer

AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wg9noPJ
via IFTTT

Read More

Government may lift price cap on cancer drugs making them costlier by up to 50%

India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy agents, faced shortages due to rising raw material costs. The government may allow significant price increases to boost production. This move aims to prevent treatment disruptions for thousands of patients across the nation. Revised prices are expected soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TVo6ZdO
via IFTTT

Read More

India's healthcare transformed in 12 years under PM Modi: Report

India's healthcare sector has seen a major transformation over the last 12 years. Health insurance coverage has expanded significantly. Maternal and child healthcare has improved. Medical infrastructure has seen a substantial increase. The government has focused on making healthcare accessible and affordable for all citizens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JnAVjwk
via IFTTT

Read More

Hetero partners with Richter to develop, market Semaglutide injection globally

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to expand global access to diabetes therapies. Regulatory filings are underway, with EU and US submissions planned for 2027. The partnership leverages Hetero's market presence and Richter's European network.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xtu7rKd
via IFTTT

Read More

Insider trading: Supreme Court upholds SAT clearance to Biocon MD

The Supreme Court has backed a tribunal's decision, clearing Biocon's managing director, Shreehas P Tambe, of insider trading allegations from 2017. The Securities and Exchange Board of India's appeal was rejected. Tambe was accused of trading Biocon shares while possessing unpublished price-sensitive information.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z6uFayf
via IFTTT

Read More